Skip to main content
Premium Trial:

Request an Annual Quote

Ignyta, Leiden U Medical Center Evaluate Epigenetic Signatures for Synovitis, RA

NEW YORK (GenomeWeb News) – Autoimmune molecular diagnostics firm Ignyta today said it is working with Leiden University Medical Center to evaluate epigenetic signatures of patients with early synovitis and rheumatoid arthritis.

Financial and other terms of the collaboration were not disclosed.

"With the signing of this collaboration with LUMC, Ignyta now has a global reach to study patients with undifferentiated arthritis and rheumatoid arthritis, taking us another step closer to achieving our goal of developing a diagnostic assay for patients with early RA," Jonathan Lim, co-founder, chairman, and CEO of Ignyta, said in a statement.

Based in San Diego, Ignyta was founded in 2011 with technology licensed from the University of California, San Diego. The company was formerly called NexDx. Last month, it announced it raised $5.5 million in an expanded Series B financing round.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.